Stryker Corporation $SYK Stock: Middleton & Co. Inc. MA Cuts Stake

Middleton & Co. Inc. MA lowered its holdings in shares of Stryker Corporation (NYSE:SYK) by 6.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,995 shares of the medical technology company’s stock after selling 1,633 shares during the quarter. Middleton & Co. Inc. MA’s holdings in Stryker were worth $6,333,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Amundi boosted its stake in shares of Stryker by 18.3% during the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after acquiring an additional 192,447 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after acquiring an additional 65,333 shares during the period. Veritas Asset Management LLP purchased a new stake in shares of Stryker in the 2nd quarter worth $168,057,000. Bank of America Corp DE purchased a new stake in shares of Stryker in the 2nd quarter worth $1,404,284,000. Finally, Rakuten Investment Management Inc. purchased a new stake in shares of Stryker in the 2nd quarter worth $18,646,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $307.65 on Friday. The company has a market capitalization of $118.01 billion, a P/E ratio of 31.88, a P/E/G ratio of 1.98 and a beta of 0.78. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33. The firm’s 50 day simple moving average is $295.23 and its two-hundred day simple moving average is $311.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts expect that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling

In other Stryker news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 351,267 shares of company stock valued at $118,197,701. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on SYK shares. Truist Financial decreased their target price on Stryker from $340.00 to $310.00 and set a “hold” rating on the stock in a report on Tuesday, October 6th. Stifel Nicolaus cut their price target on Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Finally, Piper Sandler decreased their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $369.00.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.